Vericel (NASDAQ:VCEL) released its earnings results on Monday, March 5th. The biotechnology company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.13, Morningstar.com reports. Vericel had a negative net margin of 27.04% and a negative return on equity of 98.77%. The company had revenue of $23.35 million for the quarter.
Shares of NASDAQ:VCEL opened at $9.95 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.86 and a quick ratio of 3.57. The company has a market capitalization of $353.46, a price-to-earnings ratio of -18.77 and a beta of 3.15. Vericel has a 12-month low of $2.35 and a 12-month high of $12.80.
Hedge funds have recently made changes to their positions in the company. Kopp Investment Advisors LLC raised its stake in Vericel by 246.0% in the 4th quarter. Kopp Investment Advisors LLC now owns 293,070 shares of the biotechnology company’s stock valued at $1,597,000 after purchasing an additional 208,368 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in Vericel in the 4th quarter valued at $105,000. Consonance Capital Management LP grew its holdings in Vericel by 11.8% in the 4th quarter. Consonance Capital Management LP now owns 3,381,303 shares of the biotechnology company’s stock valued at $18,428,000 after buying an additional 356,969 shares in the last quarter. RTW Investments LP purchased a new stake in Vericel in the 4th quarter valued at $7,111,000. Finally, Broadfin Capital LLC purchased a new stake in Vericel in the 4th quarter valued at $472,000. 37.22% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/03/30/vericel-vcel-posts-quarterly-earnings-results-beats-expectations-by-0-13-eps/1973681.html.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.